Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease.
Journal
Nature reviews. Nephrology
ISSN: 1759-507X
Titre abrégé: Nat Rev Nephrol
Pays: England
ID NLM: 101500081
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
accepted:
26
06
2023
medline:
18
9
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
Chronic kidney disease (CKD) is a global health problem with rising incidence and prevalence. Among several pathogenetic mechanisms responsible for disease progression, lipid accumulation in the kidney parenchyma might drive inflammation and fibrosis, as has been described in fatty liver diseases. Lipids and their metabolites have several important structural and functional roles, as they are constituents of cell and organelle membranes, serve as signalling molecules and are used for energy production. However, although lipids can be stored in lipid droplets to maintain lipid homeostasis, lipid accumulation can become pathogenic. Understanding the mechanisms linking kidney parenchymal lipid accumulation to CKD of metabolic or non-metabolic origin is challenging, owing to the tremendous variety of lipid species and their functional diversity across different parenchymal cells. Nonetheless, multiple research reports have begun to emphasize the effect of dysregulated kidney lipid metabolism in CKD progression. For example, altered cholesterol and fatty acid metabolism contribute to glomerular and tubular cell injury. Newly developed lipid-targeting agents are being tested in clinical trials in CKD, raising expectations for further therapeutic development in this field.
Identifiants
pubmed: 37500941
doi: 10.1038/s41581-023-00741-w
pii: 10.1038/s41581-023-00741-w
doi:
Substances chimiques
Lipids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-645Informations de copyright
© 2023. Springer Nature Limited.
Références
Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic kidney disease. Lancet 389, 1238–1252 (2017).
pubmed: 27887750
Shankland, S. J., Freedman, B. S. & Pippin, J. W. Can podocytes be regenerated in adults? Curr. Opin. Nephrol. Hypertens. 26, 154–164 (2017).
pubmed: 28306565
pmcid: 5511735
Lasagni, L. et al. Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Stem Cell Rep. 5, 248–263 (2015).
Kaverina, N. V., Eng, D. G., Schneider, R. R., Pippin, J. W. & Shankland, S. J. Partial podocyte replenishment in experimental FSGS derives from nonpodocyte sources. Am. J. Physiol. Renal Physiol. 310, F1397–F1413 (2016).
pubmed: 27076646
pmcid: 4935768
Hackl, M. J. et al. Tracking the fate of glomerular epithelial cells in vivo using serial multiphoton imaging in new mouse models with fluorescent lineage tags. Nat. Med. 19, 1661–1666 (2013).
pubmed: 24270544
pmcid: 3884556
Humphreys, B. D. Mechanisms of renal fibrosis. Annu. Rev. Physiol. 80, 309–326 (2018).
pubmed: 29068765
Emanuelsson, F., Nordestgaard, B. G. & Benn, M. Familial hypercholesterolemia and risk of peripheral arterial disease and chronic kidney disease. J. Clin. Endocrinol. Metab. 103, 4491–4500 (2018).
pubmed: 30085243
Weldegiorgis, M. & Woodward, M. Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom. BMC Nephrol. 23, 312 (2022).
pubmed: 36109725
pmcid: 9479392
Pauley, M. E. et al. Triglyceride content of lipoprotein subclasses and kidney hemodynamic function and injury in adolescents with type 1 diabetes. J. Diabetes Complicat. 37, 108384 (2023).
Rubinow, K. B. et al. Kidney function is associated with an altered protein composition of high-density lipoprotein. Kidney Int. 92, 1526–1535 (2017).
pubmed: 28754556
pmcid: 5696089
Herman-Edelstein, M., Scherzer, P., Tobar, A., Levi, M. & Gafter, U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid Res. 55, 561–572 (2014).
pubmed: 24371263
pmcid: 3934740
Merscher-Gomez, S. et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes 62, 3817–3827 (2013).
pubmed: 23835338
pmcid: 3806621
Ducasa, G. M. et al. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. J. Clin. Invest. 129, 3387–3400 (2019).
pubmed: 31329164
pmcid: 6668702
Proctor, G. et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in akita and OVE26 mice with type 1 diabetes. Diabetes 55, 2502–2509 (2006).
pubmed: 16936198
Meyrier, A. Nephrosclerosis: a term in quest of a disease. Nephron 129, 276–282 (2015).
pubmed: 25871843
Haruyama, N. et al. Subclinical nephrosclerosis is linked to left ventricular hypertrophy independent of classical atherogenic factors. Hypertens. Res. 37, 472–477 (2014).
pubmed: 24305517
Lovric, S. et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J. Clin. Invest. 127, 912–928 (2017).
pubmed: 28165339
pmcid: 5330730
Prasad, R. et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J. Clin. Invest. 127, 942–953 (2017).
pubmed: 28165343
pmcid: 5330744
Müller-Deile, J. et al. Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent focal segmental glomerulosclerosis. Sci. Rep. 11, 4577 (2021).
pubmed: 33633212
pmcid: 7907124
Vivarelli, M., Massella, L., Ruggiero, B. & Emma, F. Minimal change disease. Clin. J. Am. Soc. Nephrol. 12, 332–345 (2017).
pubmed: 27940460
Mitrofanova, A. et al. Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Kidney Int. 94, 1151–1159 (2018).
pubmed: 30301568
pmcid: 6278936
Liu, X. et al. Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome. Kidney Int. 98, 1275–1285 (2020).
pubmed: 32739420
pmcid: 7606642
Ding, W. et al. Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight 3, e94818 (2018).
pubmed: 29563333
pmcid: 5926939
Su, X. et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am. J. Kidney Dis. 67, 881–892 (2016).
pubmed: 26905361
Shamburek, R. D. et al. Familial lecithin:cholesterol acyltransferase deficiency: first-in-human treatment with enzyme replacement. J. Clin. Lipidol. 10, 356–367 (2016).
pubmed: 27055967
Rickards, E. Remarks on the fatty transformation of the kidney. Br. Med. J. 2, 2–3 (1883).
pubmed: 20750672
pmcid: 2372695
Minami, S. et al. Lipophagy maintains energy homeostasis in the kidney proximal tubule during prolonged starvation. Autophagy 13, 1629–1647 (2017).
pubmed: 28813167
pmcid: 5640178
Zhao, C. et al. PACS-2 deficiency in tubular cells aggravates lipid-related kidney injury in diabetic kidney disease. Mol. Med. 28, 117 (2022).
pubmed: 36138342
pmcid: 9502582
Csaki, L. S. et al. Lipin-1 and lipin-3 together determine adiposity in vivo. Mol. Metab. 3, 145–154 (2014).
pubmed: 24634820
Liu, X., Du, H., Sun, Y. & Shao, L. Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention. Ren. Fail. 44, 790–805 (2022).
pubmed: 35535500
pmcid: 9103584
Czajka, A. & Malik, A. N. Hyperglycemia induced damage to mitochondrial respiration in renal mesangial and tubular cells: Implications for diabetic nephropathy. Redox Biol. 10, 100–107 (2016).
pubmed: 27710853
pmcid: 5053113
Forbes, J. M. & Thorburn, D. R. Mitochondrial dysfunction in diabetic kidney disease. Nat. Rev. Nephrol. 14, 291–312 (2018).
pubmed: 29456246
Khan, S. et al. Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression. JCI Insight 5, e136845 (2020).
pubmed: 32614804
pmcid: 7455077
Tsai, I. T. et al. FABP1 and FABP2 as markers of diabetic nephropathy. Int. J. Med. Sci. 17, 2338–2345 (2020).
pubmed: 32922199
pmcid: 7484639
Yokoi, H. & Yanagita, M. Targeting the fatty acid transport protein CD36, a class B scavenger receptor, in the treatment of renal disease. Kidney Int. 89, 740–742 (2016).
pubmed: 26994570
Alkhatatbeh, M. J., Enjeti, A. K., Acharya, S., Thorne, R. F. & Lincz, L. F. The origin of circulating CD36 in type 2 diabetes. Nutr. Diabetes 3, e59–e59 (2013).
pubmed: 23381664
pmcid: 3584987
Kim, H. J. et al. A novel index using soluble CD36 is associated with the prevalence of type 2 diabetes mellitus: comparison study with triglyceride-glucose index. Endocrinol. Metab. 32, 375–382 (2017).
Shiju, T. M., Mohan, V., Balasubramanyam, M. & Viswanathan, P. Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy. J. Diabetes Complicat. 29, 400–406 (2015).
Ekici, M., Kisa, U., Arikan Durmaz, S., Ugur, E. & Nergiz-Unal, R. Fatty acid transport receptor soluble CD36 and dietary fatty acid pattern in type 2 diabetic patients: a comparative study. Br. J. Nutr. 119, 153–162 (2018).
pubmed: 29359682
Castelblanco, E. et al. Circulating soluble CD36 is similar in type 1 and type 2 diabetes mellitus versus non-diabetic subjects. J. Clin. Med. 8, 710 (2019).
pubmed: 31109109
pmcid: 6571689
Thi, T. N. D., Gia, B. N., Thi, H. L. L., Thi, T. N. C. & Thanh, H. P. Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J. Med. Biochem. 39, 224–230 (2020).
pubmed: 33033456
pmcid: 7526021
Ito, H. et al. Current metabolic status affects urinary liver-type fatty-acid binding protein in normoalbuminuric patients with type 2 diabetes. J. Clin. Med. Res. 9, 366–373 (2017).
pubmed: 28270898
pmcid: 5330781
Tanaka, M. et al. Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria. BMC Nephrol. 21, 459 (2020).
pubmed: 33143633
pmcid: 7640424
Su, H.-Y., Hsu, B.-G., Lin, Y.-L., Wang, C.-H. & Lai, Y.-H. Serum adipocyte fatty acid-binding protein level is positively associated with aortic stiffness in nondialysis chronic kidney disease patients: a cross-sectional study. Medicine 101, e29558 (2022).
pubmed: 35866771
pmcid: 9302354
Houten, S. M., Wanders, R. J. A. & Ranea-Robles, P. Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165720 (2020).
pubmed: 32057943
pmcid: 7146961
Violante, S. et al. Peroxisomes can oxidize medium- and long-chain fatty acids through a pathway involving ABCD3 and HSD17B4. FASEB J. 33, 4355–4364 (2019).
pubmed: 30540494
Nakagawa, S. et al. Molecular markers of tubulointerstitial fibrosis and tubular cell damage in patients with chronic kidney disease. PLoS One 10, e0136994 (2015).
pubmed: 26317775
pmcid: 4552842
Woroniecka, K. I. et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 60, 2354–2369 (2011).
pubmed: 21752957
pmcid: 3161334
Sun, H., Yuan, Y. & Sun, Z. L. Cholesterol contributes to diabetic nephropathy through SCAP-SREBP-2 pathway. Int. J. Endocrinol. 2013, 592576 (2013).
pubmed: 24369464
pmcid: 3863482
Yang, X. et al. CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat. Rev. Nephrol. 13, 769–781 (2017).
pubmed: 28919632
Yang, X. et al. CD36 promotes podocyte apoptosis by activating the pyrin domain-containing-3 (NLRP3) inflammasome in primary nephrotic syndrome. Med. Sci. Monit. 24, 6832–6839 (2018).
pubmed: 30258045
pmcid: 6178869
Kim, J. J. et al. Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome. EBioMedicine 63, 103162 (2021).
pubmed: 33340991
Wei Hua, L. P. et al. CD36-mediated podocyte lipotoxicity promotes foot process effacement. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-2454690/v1 (2023).
doi: 10.21203/rs.3.rs-2454690/v1
pubmed: 37609340
Gao, Q. et al. Overexpression of heart-type fatty acid binding protein enhances fatty acid-induced podocyte injury. Exp. Ther. Med. 15, 2054–2061 (2018).
pubmed: 29434805
Chen, H. M., Zheng, C. X., Gao, Q., Ge, Y. C. & Liu, Z. H. Heart-type fatty acid binding protein is associated with proteinuria in obesity. PLoS One 7, e45691 (2012).
pubmed: 23029183
pmcid: 3445507
Falkevall, A. et al. Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease. Cell Metab. 25, 713–726 (2017).
pubmed: 28190774
Bobulescu, I. A. Renal lipid metabolism and lipotoxicity. Curr. Opin. Nephrol. Hypertens. 19, 393–402 (2010).
pubmed: 20489613
pmcid: 3080272
Rahman, M. et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin. J. Am. Soc. Nephrol. 9, 1190–1198 (2014).
pubmed: 24832097
pmcid: 4078958
Feng, L., Gu, C., Li, Y. & Huang, J. High glucose promotes CD36 expression by upregulating peroxisome proliferator-activated receptor γ levels to exacerbate lipid deposition in renal tubular cells. Biomed. Res. Int. 2017, 1414070 (2017).
pubmed: 28497039
pmcid: 5405368
Kennedy, D. J. et al. CD36 and Na/K-ATPase-α1 form a proinflammatory signaling loop in kidney. Hypertension 61, 216–224 (2013).
pubmed: 23172921
Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37–46 (2015).
pubmed: 25419705
Khan, S. et al. Kidney proximal tubule lipoapoptosis is regulated by fatty acid transporter-2 (FATP2). J. Am. Soc. Nephrol. 29, 81–91 (2018).
pubmed: 28993506
Chen, Y. et al. Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis. Cell Death Dis. 11, 994 (2020).
pubmed: 33219209
pmcid: 7679409
Cheng, L. et al. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch. Toxicol. 92, 469–485 (2018).
pubmed: 28871336
Bryant, C. et al. Alternatively spliced landscape of PPARγ mRNA in podocytes is distinct from adipose tissue. Cells 11, 3455 (2022).
pubmed: 36359851
pmcid: 9653906
Pistrosch, F. et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54, 2206–2211 (2005).
pubmed: 15983223
Agarwal, R. et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 68, 285–292 (2005).
pubmed: 15954919
Park, C. W. et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55, 885–893 (2006).
pubmed: 16567507
Matsushita, Y. et al. Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes 60, 960–968 (2011).
pubmed: 21270242
pmcid: 3046857
Declèves, A. E. et al. Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int. 85, 611–623 (2014).
pubmed: 24304883
Hong, Q. et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 93, 1330–1343 (2018).
pubmed: 29477240
pmcid: 5967974
Wang, Q. et al. Faster lipid β-oxidation rate by acetyl-CoA carboxylase 2 inhibition alleviates high-glucose-induced insulin resistance via SIRT1/PGC-1α in human podocytes. J. Biochem. Mol. Toxicol. 35, e22797 (2021).
pubmed: 33957017
Woo, C. Y. et al. Inhibition of ceramide accumulation in podocytes by myriocin prevents diabetic nephropathy. Diabetes Metab. J. 44, 581–591 (2020).
pubmed: 31701696
Fucho, R., Casals, N., Serra, D. & Herrero, L. Ceramides and mitochondrial fatty acid oxidation in obesity. FASEB J. 31, 1263–1272 (2017).
pubmed: 28003342
Chen, Y. et al. The inhibition of Nrf2 accelerates renal lipid deposition through suppressing the ACSL1 expression in obesity-related nephropathy. Ren. Fail. 41, 821–831 (2019).
pubmed: 31488013
pmcid: 6735294
Maeda, S. et al. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet. 6, e1000842 (2010).
pubmed: 20168990
pmcid: 2820513
Shah, V. N. et al. ACACβ gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes. Mol. Cell Biochem. 372, 191–198 (2013).
pubmed: 23081748
Kayampilly, P., Roeser, N., Rajendiran, T. M., Pennathur, S. & Afshinnia, F. Acetyl Co-A carboxylase inhibition halts hyperglycemia induced upregulation of de novo lipogenesis in podocytes and proximal tubular cells. Metabolites 12, 940 (2022).
pubmed: 36295842
pmcid: 9610518
Lee, M. et al. Phosphorylation of acetyl-CoA carboxylase by AMPK reduces renal fibrosis and is essential for the anti-fibrotic effect of metformin. J. Am. Soc. Nephrol. 29, 2326–2336 (2018).
pubmed: 29976587
pmcid: 6115654
Dhillon, P. et al. The nuclear receptor ESRRA protects from kidney disease by coupling metabolism and differentiation. Cell Metab. 33, 379–394.e378 (2021).
pubmed: 33301705
Iwaki, T. et al. PPARα contributes to protection against metabolic and inflammatory derangements associated with acute kidney injury in experimental sepsis. Physiol. Rep. 7, e14078 (2019).
pubmed: 31102342
pmcid: 6525329
Jang, H. S. et al. Proximal tubule cyclophilin D regulates fatty acid oxidation in cisplatin-induced acute kidney injury. Kidney Int. 97, 327–339 (2020).
pubmed: 31733829
Chung, K. W. et al. Impairment of PPARα and the fatty acid oxidation pathway aggravates renal fibrosis during aging. J. Am. Soc. Nephrol. 29, 1223–1237 (2018).
pubmed: 29440279
pmcid: 5875952
Li, J. et al. STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation. Cell Death Dis. 13, 66 (2022).
pubmed: 35046382
pmcid: 8770798
Jao, T. M. et al. ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney Int. 95, 577–589 (2019).
pubmed: 30639234
Darshi, M. et al. Crabtree effect in kidney proximal tubule cells via late-stage glycolytic intermediates. iScience 26, 106462 (2023).
pubmed: 37091239
pmcid: 10119590
Song, J., Yang, X. & Yan, L. J. Role of pseudohypoxia in the pathogenesis of type 2 diabetes. Hypoxia 7, 33–40 (2019).
pubmed: 31240235
pmcid: 6560198
Menezes, L. F., Lin, C. C., Zhou, F. & Germino, G. G. Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. EBioMedicine 5, 183–192 (2016).
pubmed: 27077126
pmcid: 4816756
Lakhia, R. et al. PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice. Am. J. Physiol. Renal Physiol. 314, F122–F131 (2018).
pubmed: 28903946
Jiang, T., Liebman, S. E., Lucia, M. S., Li, J. & Levi, M. Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int. 68, 2608–2620 (2005).
pubmed: 16316337
Chung, K. W. et al. PPARα/β activation alleviates age-associated renal fibrosis in Sprague Dawley rats. J. Gerontol. A Biol. Sci. Med. Sci. 75, 452–458 (2020).
pubmed: 31112599
Miguel, V. et al. Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis. J. Clin. Invest, 131, e140695 (2021).
pubmed: 33465052
Piret, S. E. et al. Loss of proximal tubular transcription factor Krüppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation. Kidney Int. 100, 1250–1267 (2021).
pubmed: 34634362
pmcid: 8608748
Chung, K. W. et al. Mitochondrial damage and activation of the STING pathway lead to renal inflammation and fibrosis. Cell Metab. 30, 784–799.e785 (2019).
pubmed: 31474566
pmcid: 7054893
Hashimoto, T. Peroxisomal β-oxidation: enzymology and molecular biology. Ann. N. Y. Acad. Sci. 804, 86–98 (1996).
pubmed: 8993538
Chang, C. L. et al. Spastin tethers lipid droplets to peroxisomes and directs fatty acid trafficking through ESCRT-III. J. Cell Biol. 218, 2583–2599 (2019).
pubmed: 31227594
pmcid: 6683741
Ding, L. et al. Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. Nat. Metab. 3, 1648–1661 (2021).
pubmed: 34903883
pmcid: 8688145
Gulati, S. et al. Ischemia-reperfusion injury: biochemical alterations in peroxisomes of rat kidney. Arch. Biochem. Biophys. 295, 90–100 (1992).
pubmed: 1575521
Ibrahim, I. Y., Elbassuoni, E. A., Ragy, M. M. & Habeeb, W. N. Gender difference in the development of cardiac lesions following acute ischemic-reperfusion renal injury in albino rats. Gen. Physiol. Biophys. 32, 421–428 (2013).
pubmed: 23846259
Negishi, K. et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int. 72, 348–358 (2007).
pubmed: 17495861
Wang, Y. et al. Peroxisome-generated succinate induces lipid accumulation and oxidative stress in the kidneys of diabetic mice. J. Biol. Chem. 298, 101660 (2022).
pubmed: 35124006
pmcid: 8881667
Dhaunsi, G. S. & Bitar, M. S. Antioxidants attenuate diabetes-induced activation of peroxisomal functions in the rat kidney. J. Biomed. Sci. 11, 566–570 (2004).
pubmed: 15316130
Hwang, I. et al. Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction. Diabetes 61, 728–738 (2012).
pubmed: 22315314
pmcid: 3282807
Sas, K. M. et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight 1, e86976 (2016).
pubmed: 27699244
pmcid: 5033761
Baek, J. et al. The deacylase sirtuin 5 reduces malonylation in nonmitochondrial metabolic pathways in diabetic kidney disease. J. Biol. Chem. 299, 102960 (2023).
pubmed: 36736426
pmcid: 9996370
Joven, J. et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N. Engl. J. Med. 323, 579–584 (1990).
pubmed: 2381443
Valdete, T.-S. & Valdete, H. in Cellular Metabolism and Related Disorders Ch. 9 (eds Khan, J. & Hsieh, P.-S.) (IntechOpen, 2019).
Vaziri, N. D., Sato, T. & Liang, K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int. 63, 1756–1763 (2003).
pubmed: 12675851
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).
pubmed: 21663949
pmcid: 3145073
Jiang, T. et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56, 2485–2493 (2007).
pubmed: 17660268
Wang, X. X. et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am. J. Physiol. Renal Physiol. 297, F1587–F1596 (2009).
pubmed: 19776172
pmcid: 2801344
Wang, X. X. et al. FXR/TGR5 Dual agonist prevents progression of nephropathy in diabetes and obesity. J. Am. Soc. Nephrol. 29, 118–137 (2018).
pubmed: 29089371
Levy, E. et al. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. 18, 310–318 (2007).
pubmed: 17495606
Caldas, Y. A. et al. Liver X receptor-activating ligands modulate renal and intestinal sodium-phosphate transporters. Kidney Int. 80, 535–544 (2011).
pubmed: 21677638
pmcid: 3428205
Liu, P. et al. Association between LXR-α and ABCA1 gene polymorphisms and the risk of diabetic kidney disease in patients with type 2 diabetes mellitus in a Chinese Han population. J. Diabetes Res. 2020, 8721536 (2020).
pubmed: 33426085
pmcid: 7772016
Pedigo, C. E. et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J. Clin. Invest. 126, 3336–3350 (2016).
pubmed: 27482889
pmcid: 5004940
Wright, M. B. et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat. Commun. 12, 4662 (2021).
pubmed: 34341345
pmcid: 8329197
Byun, J. H. et al. Inhibitory antibodies against PCSK9 reduce surface CD36 and mitigate diet-induced renal lipotoxicity. Kidney360 3, 1394–1410 (2022).
pubmed: 36176646
pmcid: 9416829
Haas, M. E. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 134, 61–72 (2016).
pubmed: 27358438
pmcid: 5345853
Buraczynska, M., Jacob, J., Gwiazda-Tyndel, K. & Ksiazek, A. LDLR gene polymorphism (rs688) affects susceptibility to cardiovascular disease in end-stage kidney disease patients. BMC Nephrol. 22, 316 (2021).
pubmed: 34556050
pmcid: 8459523
Guo, Q., Feng, X. & Zhou, Y. PCSK9 variants in familial hypercholesterolemia: a comprehensive synopsis. Front. Genet. 11, 1020 (2020).
pubmed: 33173529
pmcid: 7538608
Yang, Q. et al. Sirt6 deficiency aggravates angiotensin II-induced cholesterol accumulation and injury in podocytes. Theranostics 10, 7465–7479 (2020).
pubmed: 32642006
pmcid: 7330847
Fu, Y. et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism. Cell Metab. 32, 1052–1062.e1058 (2020).
pubmed: 33186558
Vaziri, N. D., Kim, C. H., Phan, D., Kim, S. & Liang, K. Up-regulation of hepatic Acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int. 66, 262–267 (2004).
pubmed: 15200432
Zhong, F. et al. ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome. Lipids Health Dis. 21, 38 (2022).
pubmed: 35399079
pmcid: 8996604
Liu, J. et al. A novel role of angiopoietin-like-3 associated with podocyte injury. Pediatr. Res. 77, 732–739 (2015).
pubmed: 25710887
Chen, W. et al. Atgl deficiency induces podocyte apoptosis and leads to glomerular filtration barrier damage. FEBS J. 284, 1070–1081 (2017).
pubmed: 28194887
Freedman, B. I., Limou, S., Ma, L. & Kopp, J. B. APOL1-associated nephropathy: a key contributor to racial disparities in CKD. Am. J. Kidney Dis. 72, S8–s16 (2018).
pubmed: 30343724
pmcid: 6200346
Ge, M. et al. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis. Hum. Mol. Genet. 30, 182–197 (2021).
pubmed: 33517446
pmcid: 8091039
Chun, J. et al. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity. Proc. Natl Acad. Sci. USA 116, 3712–3721 (2019).
pubmed: 30733285
pmcid: 6397558
Zhao, K. et al. Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. Sci. Rep. 6, 37234 (2016).
pubmed: 27853248
pmcid: 5112546
Kim, D. H. et al. Src-mediated crosstalk between FXR and YAP protects against renal fibrosis. FASEB J. 33, 11109–11122 (2019).
pubmed: 31298930
Zhou, W. & Anakk, S. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. Mol. Cell. Endocrinol. 549, 111616 (2022).
pubmed: 35304191
pmcid: 9245558
Kim, D.-H. et al. The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases. Exp. Mol. Med. 55, 304–312 (2023).
pubmed: 36737665
pmcid: 9981614
Zhou, B. et al. Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy. Mol. Cell Endocrinol. 419, 72–82 (2016).
pubmed: 26450152
Wu, D. et al. Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid β‐oxidation. J. Am. Heart Assoc. 9, e014358 (2020).
pubmed: 31870234
Wu, M. M. et al. Lovastatin attenuates hypertension induced by renal tubule-specific knockout of ATP-binding cassette transporter A1, by inhibiting epithelial sodium channels. Br. J. Pharmacol. 176, 3695–3711 (2019).
pubmed: 31222723
pmcid: 6715779
Tsun, J. G. et al. Cellular cholesterol transport proteins in diabetic nephropathy. PLoS One 9, e105787 (2014).
pubmed: 25181357
pmcid: 4152117
Baumer, Y., McCurdy, S. G. & Boisvert, W. A. Formation and cellular impact of cholesterol crystals in health and disease. Adv. Biol. 5, 2100638 (2021).
Del Sordo, R. et al. Cholesterol crystals tubulointerstitial injury during nephrotic syndrome; can be classified as tubular crystallopathy? J. Nephropathol. 10, e20–e20 (2021).
Olzmann, J. A. & Carvalho, P. Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell Biol. 20, 137–155 (2019).
pubmed: 30523332
pmcid: 6746329
Cui, L. & Liu, P. Two types of contact between lipid droplets and mitochondria. Front. Cell Dev. Biol. 8, 618322 (2020).
pubmed: 33385001
pmcid: 7769837
Yang, W. et al. Ectopic lipid accumulation: potential role in tubular injury and inflammation in diabetic kidney disease. Clin. Sci. 132, 2407–2422 (2018).
Kume, S. et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J. Am. Soc. Nephrol. 18, 2715–2723 (2007).
pubmed: 17855643
Saito, K. et al. Lipid accumulation and transforming growth factor-β upregulation in the kidneys of rats administered angiotensin II. Hypertension 46, 1180–1185 (2005).
pubmed: 16203876
Kiss, E. et al. Lipid droplet accumulation is associated with an increase in hyperglycemia-induced renal damage: prevention by liver X receptors. Am. J. Pathol. 182, 727–741 (2013).
pubmed: 23318573
Pérez-Martí, A. et al. Reducing lipid bilayer stress by monounsaturated fatty acids protects renal proximal tubules in diabetes. eLife 11, e74391 (2022).
pubmed: 35550039
pmcid: 9154741
Xie, Y. H. et al. Role of the CTRP6/AMPK pathway in kidney fibrosis through the promotion of fatty acid oxidation. Eur. J. Pharmacol. 892, 173755 (2021).
pubmed: 33245899
Liu, L. et al. Twist1 downregulation of PGC-1α decreases fatty acid oxidation in tubular epithelial cells, leading to kidney fibrosis. Theranostics 12, 3758–3775 (2022).
pubmed: 35664054
pmcid: 9131259
Chen, Z. et al. Oxidative stress and lipid dysregulation in lipid droplets: a connection to chronic kidney disease revealed in human kidney cells. Antioxidants 11, 1387 (2022).
pubmed: 35883878
pmcid: 9312214
Lubojemska, A. et al. Adipose triglyceride lipase protects renal cell endocytosis in a Drosophila dietary model of chronic kidney disease. PLoS Biol. 19, e3001230 (2021).
pubmed: 33945525
pmcid: 8121332
Chen, R.-X. et al. The renal manifestations of type 4 familial partial lipodystrophy: a case report and review of literature. BMC Nephrol. 19, 111 (2018).
pubmed: 29747582
pmcid: 5946515
Wang, Y. et al. Perilipin expression in human adipose tissues: effects of severe obesity, gender, and depot. Obes. Res. 11, 930–936 (2003).
pubmed: 12917496
Ju, L. et al. Obesity-associated inflammation triggers an autophagy–lysosomal response in adipocytes and causes degradation of perilipin 1. Cell Death Dis. 10, 121 (2019).
pubmed: 30741926
pmcid: 6370809
Jun, H. et al. In vivo and in vitro effects of SREBP-1 on diabetic renal tubular lipid accumulation and RNAi-mediated gene silencing study. Histochem. Cell Biol. 131, 327–345 (2009).
pubmed: 19048273
Kim, J. J. et al. British Society for Matrix Biology spring 2022 meeting. Int. J. Exp. Pathol. 103, A1–A8 (2022).
Mallela, S. K. et al. Sphingomyelin phosphodiesterase acid like 3B (SMPDL3b) regulates Perilipin5 (PLIN5) expression and mediates lipid droplet formation. Genes Dis. 9, 1397–1400 (2022).
pubmed: 35224168
pmcid: 8861840
Mitrofanova, A. et al. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease. Nat. Commun. 10, 2692 (2019).
pubmed: 31217420
pmcid: 6584700
Mallela, S. K., Mitrofanova, A., Merscher, S. & Fornoni, A. Regulation of the amount of ceramide-1-phosphate synthesized in differentiated human podocytes. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864, 158517 (2019).
pubmed: 31487557
pmcid: 6832884
Feng, J. et al. Perilipin 5 ameliorates high-glucose-induced podocyte injury via Akt/GSK-3β/Nrf2-mediated suppression of apoptosis, oxidative stress, and inflammation. Biochem. Biophys. Res. Commun. 544, 22–30 (2021).
pubmed: 33516878
Yoshioka, K. et al. Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease. Kidney Int. 101, 510–526 (2022).
pubmed: 34856312
Li, H., Dixon, E. E., Wu, H. & Humphreys, B. D. Comprehensive single-cell transcriptional profiling defines shared and unique epithelial injury responses during kidney fibrosis. Cell Metab. 34, 1977–1998.e1979 (2022).
pubmed: 36265491
Sørensen, I. M. et al. Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis 275, 304–311 (2018).
pubmed: 29980057
Drexler, Y. et al. Identification of glomerular and plasma apolipoprotein M as novel biomarkers in glomerular disease. Kidney Int. Rep. 8, 884–897 (2023).
pubmed: 37069998
pmcid: 10105063
Ferrans, V. J. & Fredrickson, D. S. The pathology of Tangier disease. A light and electron microscopic study. Am. J. Pathol. 78, 101–158 (1975).
pubmed: 162820
pmcid: 1915033
Mende, C. & Einhorn, D. Fatty kidney disease: the importance of ectopic fat deposition and the potential value of imaging. J. Diabetes 14, 73–78 (2022).
pubmed: 34704674
Jiang, Z. et al. Obesity and chronic kidney disease. Am. J. Physiol. Endocrinol. Metab. 324, E24–E41 (2023).
pubmed: 36383637
Chughtai, H. L. et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension 56, 901–906 (2010).
pubmed: 20837881
Wagner, R. et al. The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A. Sci. Rep. 7, 2261 (2017).
pubmed: 28536464
pmcid: 5442123
Wagner, R. et al. Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes. Diabetologia 55, 2054–2058 (2012).
pubmed: 22526613
Shen, Y. et al. Renal fat fraction is significantly associated with the risk of chronic kidney disease in patients with type 2 diabetes. Front. Endocrinol. 13, 995028 (2022).
Spit, K. A. et al. Renal sinus fat and renal hemodynamics: a cross-sectional analysis. MAGMA 33, 73–80 (2020).
pubmed: 31471702
Krievina, G. et al. Ectopic adipose tissue storage in the left and the right renal sinus is asymmetric and associated with serum kidney injury molecule-1 and fibroblast growth factor-21 levels increase. EBioMedicine 13, 274–283 (2016).
pubmed: 28005535
pmcid: 5264268
Zelicha, H. et al. Changes of renal sinus fat and renal parenchymal fat during an 18-month randomized weight loss trial. Clin. Nutr. 37, 1145–1153 (2018).
pubmed: 28501343
Schaub, J. A. et al. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth onset type 2 diabetes. J. Clin. Invest. 133, e164486 (2023).
pubmed: 36637914
pmcid: 9974101
Marzolla, V. et al. The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway. FASEB J. 34, 12450–12465 (2020).
pubmed: 32729974
Ge, M. et al. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome. eLife 12, e83353 (2023).
pubmed: 37129368
pmcid: 10185338
Hayder, Z. S. & Kareem, Z. S. Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin. Int. Urol. Nephrol. 52, 749–756 (2020).
pubmed: 32173772
Ng, X.-N., Tang, C.-C., Wang, C.-H., Tsai, J.-P. & Hsu, B.-G. Positive correlation of serum resistin level with peripheral artery disease in patients with chronic kidney disease stage 3 to 5. Int. J. Environ. Res. Public. Health 18, 12746 (2021).
pubmed: 34886472
pmcid: 8657432
Li, H.-F., Liu, H.-T., Chen, P.-Y., Lin, H. & Tseng, T.-L. Role of PVAT in obesity-related cardiovascular disease through the buffering activity of ATF3. iScience 25, 105631 (2022).
pubmed: 36458260
pmcid: 9707070
Agabiti-Rosei, C. et al. Anticontractile activity of perivascular fat in obese mice and the effect of long-term treatment with melatonin. J. Hypertens. 32, 1264–1274 (2014).
pubmed: 24751595
Wang, M. et al. Deletion of seipin attenuates vascular function and the anticontractile effect of perivascular adipose tissue. Front. Cardiovasc. Med. 8, 706924 (2021).
pubmed: 34409079
pmcid: 8365033
Zou, L. et al. Spontaneous hypertension occurs with adipose tissue dysfunction in perilipin-1 null mice. Biochim. Biophys. Acta 1862, 182–191 (2016).
pubmed: 26521150
Qi, X. Y. et al. Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword. Cardiovasc. Diabetol. 17, 134 (2018).
pubmed: 30305178
pmcid: 6180425
Ouyang, A., Olver, T. D., Emter, C. A. & Fleenor, B. S. Chronic exercise training prevents coronary artery stiffening in aortic-banded miniswine: Role of perivascular adipose-derived advanced glycation end products. J. Appl. Physiol. 127, 816–827 (2019).
pubmed: 31295062
pmcid: 6766711
Chen, X. et al. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway. J. Int. Med. Res. 49, 300060521992981 (2021).
pubmed: 33641439
Hildebrand, S., Stümer, J. & Pfeifer, A. PVAT and its relation to brown, beige, and white adipose tissue in development and function. Front. Physiol. 9, 70 (2018).
pubmed: 29467675
pmcid: 5808192
Kim, S. J., Choi, Y., Choi, Y. H. & Park, T. Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J. Nutr. Biochem. 23, 113–122 (2012).
pubmed: 21414767
Song, M. J., Kim, K. H., Yoon, J. M. & Kim, J. B. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem. Biophys. Res. Commun. 346, 739–745 (2006).
pubmed: 16781673
Kiernan, R. N., Maddie, N. & Carrillo-Sepulveda, M. A. Western diet-induced hypertension involves HMGB1/TLR4 signaling in perivascular adipose tissue of female rats. FASEB J. 34, 1–1 (2020).
Mao, Y. et al. STING-IRF3 triggers endothelial inflammation in response to free fatty acid-induced mitochondrial damage in diet-induced obesity. Arterioscler. Thromb. Vasc. Biol. 37, 920–929 (2017).
pubmed: 28302626
pmcid: 5408305
Wu, J. et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J. Clin. Invest. 131, e136329 (2021).
pubmed: 34651582
pmcid: 8516463
Yu, B. C. et al. Minimal change disease is associated with mitochondrial injury and STING pathway activation. J. Clin. Med. 11, 577 (2022).
pubmed: 35160028
pmcid: 8836778
Mitrofanova, A. et al. Activation of stimulator of IFN genes (STING) causes proteinuria and contributes to glomerular diseases. J. Am. Soc. Nephrol. 33, 2153–2173 (2022).
pubmed: 36198430
Climent, E., Benaiges, D. & Pedro-Botet, J. Hydrophilic or lipophilic statins. Front. Cardiovasc. Med. 8, 687585 (2021).
pubmed: 34095267
pmcid: 8172607
Wanner, C., Tonelli, M. & Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney Int. 85, 1303–1309 (2014).
pubmed: 24552851
Jin Kang, H. et al. Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease. Kidney Res. Clin. Pract. 32, 21–26 (2013).
pubmed: 26889433
Pham, K. O. et al. Association between vitamin intake and chronic kidney disease according to a variant located upstream of the PTGS1 gene: a cross-sectional analysis of Shika study. Nutrients 14, 2082 (2022).
pubmed: 35631221
pmcid: 9143472
Robins, S. J. et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. J. Am. Med. Assoc. 285, 1585–1591 (2001).
Imai, E. & Imai, A. Effect of pemafibrate on serum creatinine in patients with chronic kidney disease. JMA J. 5, 328–333 (2022).
pubmed: 35992291
pmcid: 9358292
Hadjivasilis, A., Kouis, P., Kousios, A. & Panayiotou, A. The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies. J. Clin. Med. 11, 768 (2022).
pubmed: 35160220
pmcid: 8836930
Hakimizadeh, E. et al. Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging. Fundam. Clin. Pharmacol. 37, 599–605 (2023).
pubmed: 36600528
Aomura, D. et al. Pemafibrate protects against fatty acid-induced nephropathy by maintaining renal fatty acid metabolism. Metabolites 11, 372 (2021).
pubmed: 34207854
pmcid: 8230306
Zheng, F. et al. Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation. Am. J. Physiol. Renal Physiol. 282, F639–F648 (2002).
pubmed: 11880325
Isshiki, K. et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49, 1022–1032 (2000).
pubmed: 10866056
Okada, T. et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 55, 1666–1677 (2006).
pubmed: 16731829
Ruan, X. Z. et al. PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J. Am. Soc. Nephrol. 14, 593–600 (2003).
pubmed: 12595494
Zhu, X. et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J. Biol. Chem. 283, 22930–22941 (2008).
pubmed: 18552351
pmcid: 2516976
Cid-Samamed, A., Rakmai, J., Mejuto, J. C., Simal-Gandara, J. & Astray, G. Cyclodextrins inclusion complex: preparation methods, analytical techniques and food industry applications. Food Chem. 384, 132467 (2022).
pubmed: 35219231
Lewandowski, C. T. et al. Metabolomic analysis of a selective ABCA1 inducer in obesogenic challenge provides a rationale for therapeutic development. EBioMedicine 66, 103287 (2021).
pubmed: 33752129
pmcid: 8010624
Yin, Q. H. et al. Exendin-4 ameliorates lipotoxicity-induced glomerular endothelial cell injury by improving ABC transporter A1-mediated cholesterol efflux in diabetic apoE knockout mice. J. Biol. Chem. 291, 26487–26501 (2016).
pubmed: 27784780
pmcid: 5159509
Schlackow, I. et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney Int. 96, 170–179 (2019).
pubmed: 31005271
pmcid: 6595178
Heinrich, N. S. et al. Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. https://doi.org/10.1111/dom.15146 (2023).
doi: 10.1111/dom.15146
pubmed: 37278273
Hua, W. et al. CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress. PLoS One 10, e0127507 (2015).
pubmed: 26000608
pmcid: 4441449
Souza, A. C. P. et al. Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation. Kidney Int. 89, 809–822 (2016).
pubmed: 26994575
pmcid: 4800337
Hou, Y. et al. The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy. Nephrol. Dial. Transplant. 33, 1908–1918 (2018).
pubmed: 30388276
Toth, P. P. et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 93, 1397–1408 (2018).
pubmed: 29526502
Charytan, D. M. et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J. Am. Coll. Cardiol. 73, 2961–2970 (2019).
pubmed: 31196453
Warden, B. A. & Duell, P. B. Inclisiran: a novel agent for lowering apolipoprotein B-containing lipoproteins. J. Cardiovasc. Pharmacol. 78, e157–e174 (2021).
pubmed: 33990512
Sakurai, M., Muso, E., Matushima, H., Ono, T. & Sasayama, S. Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. Kidney Int. Suppl. 71, S210–S212 (1999).
pubmed: 10412778
Wang, A. et al. Systematic review of low‐density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J. Am. Heart Assoc. 5, e003294 (2016).
pubmed: 27385428
pmcid: 5015370
Ai, J. Y., Zhao, P. C., Zhang, W. & Rao, G. W. Research progress in the clinical treatment of familial hypercholesterolemia. Curr. Med. Chem. https://doi.org/10.2174/0929867330666230202111849 (2023).
doi: 10.2174/0929867330666230202111849
pubmed: 37694790
Al-Mousily, M., Nicoara, O., Selewski, D. T. & Twombley, K. Liposorber® LA-15 system for LDL apheresis in resistant nephrotic syndrome patients. Pediatr. Nephrol. 37, 585–592 (2022).
pubmed: 34453196
Muso, E. et al. Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. Ther. Apher. Dial. 26, 220–228 (2022).
pubmed: 34057286
Wang, X. X. et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J. Biol. Chem. 292, 5335–5348 (2017).
pubmed: 28196866
pmcid: 5392679
Sun, H., Chen, J., Hua, Y., Zhang, Y. & Liu, Z. New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation. Diabetol. Metab. Syndr. 14, 121 (2022).
pubmed: 35999610
pmcid: 9396853
Wanner, C. et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. Diabetes Obes. Metab. 22, 2335–2347 (2020).
pubmed: 32744354
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
pubmed: 27299675
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
pubmed: 30990260
The EMPA-KIDNEY Collaborative Group et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023).
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
pubmed: 32970396
Kwon, S. et al. The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care 43, 948–955 (2020).
pubmed: 32132005
Lin, C.-X. et al. Metformin attenuates cyclosporine A-induced renal fibrosis in rats. Transplantation 103, e285–e296 (2019).
pubmed: 31335763
Satriano, J., Sharma, K., Blantz, R. C. & Deng, A. Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am. J. Physiol. Renal Physiol. 305, F727–F733 (2013).
pubmed: 23825068
pmcid: 3761200
Neven, E. et al. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int. 94, 102–113 (2018).
pubmed: 29716795
Abe, M., Okada, K. & Soma, M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr. Drug. Metab. 12, 57–69 (2011).
pubmed: 21303332
Roumie, C. L. et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. J. Am. Med. Assoc. 322, 1167–1177 (2019).
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
pubmed: 27633186
Hahr, A. J. & Molitch, M. E. Management of diabetes mellitus in patients with CKD: core curriculum 2022. Am. J. Kidney Dis. 79, 728–736 (2022).
pubmed: 34600745
Eom, M., Hudkins, K. L. & Alpers, C. E. Foam cells and the pathogenesis of kidney disease. Curr. Opin. Nephrol. Hypertens. 24, 245–251 (2015).
pubmed: 25887903
pmcid: 4466027
Kaseda, R. et al. Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism. BMC Nephrol. 19, 17 (2018).
pubmed: 29374468
pmcid: 5787279
Yan, P. et al. Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study. Acta Diabetol. 58, 1615–1625 (2021).
pubmed: 34181081
Nam, K. H. et al. Association between serum high‐density lipoprotein cholesterol levels and progression of chronic kidney disease: results from the KNOW‐CKD. J. Am. Heart Assoc. 8, e011162 (2019).
pubmed: 30859896
pmcid: 6475054
Pavanello, C. et al. Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. J. Lipid Res. 61, 1784–1788 (2020).
pubmed: 32998975
pmcid: 7707181
Tsuruya, K. et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am. J. Kidney Dis. 66, 972–983 (2015).
pubmed: 26145254
Kim, J. et al. The ratio of triglycerides to high-density lipoprotein cholesterol is associated with the risk of chronic kidney disease in Korean men. Lipids 56, 475–483 (2021).
pubmed: 34089267
Kim, Y. et al. Predictive value of triglyceride/high-density lipoprotein cholesterol for major clinical outcomes in advanced chronic kidney disease: a nationwide population-based study. Clin. Kidney J. 14, 1961–1968 (2020).
pubmed: 34345420
pmcid: 8323149
Itabe, H., Yamaguchi, T., Nimura, S. & Sasabe, N. Perilipins: a diversity of intracellular lipid droplet proteins. Lipids Health Dis. 16, 83 (2017).
pubmed: 28454542
pmcid: 5410086
Schroeder, B. et al. The small GTPase Rab7 as a central regulator of hepatocellular lipophagy. Hepatology 61, 1896–1907 (2015).
pubmed: 25565581
Kaushik, S. & Cuervo, A. M. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat. Cell Biol. 17, 759–770 (2015).
pubmed: 25961502
pmcid: 4449813
Kaushik, S. & Cuervo, A. M. AMPK-dependent phosphorylation of lipid droplet protein PLIN2 triggers its degradation by CMA. Autophagy 12, 432–438 (2016).
pubmed: 26902588
pmcid: 4835968
Shin, D. W. Lipophagy: molecular mechanisms and implications in metabolic disorders. Mol. Cell 43, 686–693 (2020).
Li, Y. et al. CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway. J. Lipid Res. 60, 844–855 (2019).
pubmed: 30662007
pmcid: 6446711
Zhang, H. et al. Dynamic MTORC1-TFEB feedback signaling regulates hepatic autophagy, steatosis and liver injury in long-term nutrient oversupply. Autophagy 14, 1779–1795 (2018).
pubmed: 30044707
pmcid: 6135624
Zhang, Z. et al. Lipophagy and liver disease: new perspectives to better understanding and therapy. Biomed. Pharmacother. 97, 339–348 (2018).
pubmed: 29091883
Han, Y. et al. Lipophagy deficiency exacerbates ectopic lipid accumulation and tubular cells injury in diabetic nephropathy. Cell Death Dis. 12, 1031 (2021).
pubmed: 34718329
pmcid: 8557213
Jung, H. S. et al. Loss of autophagy diminishes pancreatic β cell mass and function with resultant hyperglycemia. Cell Metab. 8, 318–324 (2008).
pubmed: 18840362
Zhao, Y. et al. High dose Vitamin E attenuates diabetic nephropathy via alleviation of autophagic stress. Front. Physiol. 9, 1939 (2018).
pubmed: 30719008
Liu, W. J. et al. Autophagy-lysosome pathway in renal tubular epithelial cells is disrupted by advanced glycation end products in diabetic nephropathy. J. Biol. Chem. 290, 20499–20510 (2015).
pubmed: 26100632
pmcid: 4536455
Merrick, D. et al. Identification of a mesenchymal progenitor cell hierarchy in adipose tissue. Science 364, eaav2501 (2019).
pubmed: 31023895
pmcid: 6816238
Shao, M. et al. Cellular origins of beige fat cells revisited. Diabetes 68, 1874–1885 (2019).
pubmed: 31540940
pmcid: 6754244
Cattaneo, P. et al. Parallel lineage-tracing studies establish fibroblasts as the prevailing in vivo adipocyte progenitor. Cell Rep. 30, 571–582.e572 (2020).
pubmed: 31940497
Grigoraș, A. et al. Perirenal adipose tissue-current knowledge and future opportunities. J. Clin. Med. 10, 1291 (2021).
pubmed: 33800984
pmcid: 8004049